|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alonso DF, Ripoll GV, Garona J, Iannucci
NB and Gomez DE: Metastasis: Recent discoveries and novel
perioperative treatment strategies with particular interest in the
hemostatic compound desmopressin. Curr Pharm Biotechnol.
12:1974–1980. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu Z, Wu Z, Li J, Yang X, Wang Y, Yu Y, Ye
J, Xu C, Qin W and Zhang Z: MCAM is a novel metastasis marker and
regulates spreading, apoptosis and invasion of ovarian cancer
cells. Tumour Biol. 33:1619–1628. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Durmus T, LeClair RJ, Park KS, Terzic A,
Yoon JK and Lindner V: Expression analysis of the novel gene
collagen triple helix repeat containing-1 (Cthrc1). Gene Expr
Patterns. 6:935–940. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang L, Dai DL, Su M, Martinka M, Li G and
Zhou Y: Aberrant expression of collagen triple helix repeat
containing 1 in human solid cancers. Clin Cancer Res. 12:3716–3722.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang P, Wang YC, Chen XY, Shen ZY, Cao H,
Zhang YJ, Yu J, Zhu JD, Lu YY and Fang JY: CTHRC1 is upregulated by
promoter demethylation and transforming growth factor-β1 and may be
associated with metastasis in human gastric cancer. Cancer Sci.
103:1327–1333. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ke Z, He W, Lai Y, Guo X, Chen S, Li S,
Wang Y and Wang L: Overexpression of collagen triple helix repeat
containing 1 (CTHRC1) is associated with tumour aggressiveness and
poor prognosis in human non-small cell lung cancer. Oncotarget.
5:9410–9424. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan JK, Pham H, You XJ, Cloven NG, Burger
RA, Rose GS, Van Nostrand K, Korc M, Disaia PJ and Fan H:
Suppression of ovarian cancer cell tumorigenicity and evasion of
cisplatin resistance using a truncated epidermal growth factor
receptor in a rat model. Cancer Res. 65:3243–3248. 2005.PubMed/NCBI
|
|
10
|
Phelps SL Bull, Schorge JO, Peyton MJ,
Shigematsu H, Xiang LL, Miller DS and Lea JS: Implications of EGFR
inhibition in ovarian cancer cell proliferation. Gynecol Oncol.
109:411–417. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Seshacharyulu P, Ponnusamy MP, Haridas D,
Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway
in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maihle NJ, Baron AT, Barrette BA, Boardman
CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja
SC, Lafky JM, et al: EGF/ErbB receptor family in ovarian cancer.
Cancer Treat Res. 107:247–258. 2002.PubMed/NCBI
|
|
13
|
Zhou C, Qiu L, Sun Y, Healey S, Wanebo H,
Kouttab N, Di W, Yan B and Wan Y: Inhibition of EGFR/PI3K/AKT cell
survival pathway promotes TSA's effect on cell death and migration
in human ovarian cancer cells. Int J Oncol. 29:269–278.
2006.PubMed/NCBI
|
|
14
|
Loganathan S, Kandala PK, Gupta P and
Srivastava SK: Inhibition of EGFR-AKT axis results in the
suppression of ovarian tumors in vitro and in preclinical mouse
model. PLoS One. 7:e435772012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gan Y, Shi C, Inge L, Hibner M, Balducci J
and Huang Y: Differential roles of ERK and Akt pathways in
regulation of EGFR-mediated signaling and motility in prostate
cancer cells. Oncogene. 29:4947–4958. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hwang YP, Yun HJ, Choi JH, Han EH, Kim HG,
Song GY, Kwon KI, Jeong TC and Jeong HG: Suppression of EGF-induced
tumor cell migration and matrix metalloproteinase-9 expression by
capsaicin via the inhibition of EGFR-mediated FAK/Akt, PKC/Raf/ERK,
p38 MAPK, and AP-1 signaling. Mol Nutr Food Res. 55:594–605. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hou M, Cheng Z, Shen H, He S, Li Y, Pan Y,
Feng C, Chen X, Zhang Y, Lin M, et al: High expression of CTHRC1
promotes EMT of epithelial ovarian cancer (EOC) and is associated
with poor prognosis. Oncotarget. 6:35813–35829. 2015.PubMed/NCBI
|
|
18
|
Zhou X, Hu Y, Dai L, Wang Y, Zhou J, Wang
W, Di W and Qiu L: MicroRNA-7 inhibits tumor metastasis and
reverses epithelial-mesenchymal transition through AKT/ERK1/2
inactivation by targeting EGFR in epithelial ovarian cancer. PLoS
One. 9:e967182014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cao C, Lu S, Sowa A, Kivlin R, Amaral A,
Chu W, Yang H, Di W and Wan Y: Priming with EGFR tyrosine kinase
inhibitor and EGF sensitizes ovarian cancer cells to respond to
chemotherapeutical drugs. Cancer Lett. 266:249–262. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khalil I, Brewer MA, Neyarapally T and
Runowicz CD: The potential of biologic network models in
understanding the etiopathogenesis of ovarian cancer. Gynecol
Oncol. 116:282–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kharaishvili G, Cizkova M, Bouchalova K,
Mgebrishvili G, Kolar Z and Bouchal J: Collagen triple helix repeat
containing 1 protein, periostin and versican in primary and
metastatic breast cancer: An immunohistochemical study. J Clin
Pathol. 64:977–982. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma MZ, Zhuang C, Yang XM, Zhang ZZ, Ma H,
Zhang WM, You H, Qin W, Gu J, Yang S, et al: CTHRC1 acts as a
prognostic factor and promotes invasiveness of gastrointestinal
stromal tumors by activating Wnt/PCP-Rho signaling. Neoplasia.
16:265–278, 278.e1-278.e13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim HC, Kim YS, Oh HW, Kim K, Oh SS, Kim
JT, Kim BY, Lee SJ, Choe YK, Kim DH, et al: Collagen triple helix
repeat containing 1 (CTHRC1) acts via ERK-dependent induction of
MMP9 to promote invasion of colorectal cancer cells. Oncotarget.
5:519–529. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Park EH, Kim S, Jo JY, Kim SJ, Hwang Y,
Kim JM, Song SY, Lee DK and Koh SS: Collagen triple helix repeat
containing-1 promotes pancreatic cancer progression by regulating
migration and adhesion of tumor cells. Carcinogenesis. 34:694–702.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37:(Suppl 4). S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han M, Liu M, Wang Y, Chen X, Xu J, Sun Y,
Zhao L, Qu H, Fan Y and Wu C: Antagonism of miR-21 reverses
epithelial-mesenchymal transition and cancer stem cell phenotype
through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One.
7:e395202012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang ZG, Wei JM, Qin CF, Hao K, Tian XD,
Xie K, Xie XH and Yang YM: Suppression of the epidermal growth
factor receptor inhibits epithelial-mesenchymal transition in human
pancreatic cancer PANC-1 cells. Dig Dis Sci. 57:1181–1189. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Konishi H, Takagi A, Kurita A, Kaneda N
and Matsuzaki T: PEGylated liposome IHL-305 markedly improved the
survival of ovarian cancer peritoneal metastasis in mouse. BMC
Cancer. 12:4622012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wittinger M, Vanhara P, El-Gazzar A,
Savarese-Brenner B, Pils D, Anees M, Grunt TW, Sibilia M, Holcmann
M, Horvat R, et al: hVps37A status affects prognosis and cetuximab
sensitivity in ovarian cancer. Clin Cancer Res. 17:7816–7827. 2011.
View Article : Google Scholar : PubMed/NCBI
|
